Tag Archives: mesothelioma treatments

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

There are many systemic therapies recommended for mesothelioma patients. Different therapies may work best for different patient populations. Different therapies may work better for older versus younger patients. Or, patients who have received treatment before. An international team of clinicians published a new study on this topic. They found a treatment strategy that works best for younger pre-treated patients. The Young (65 years or younger) and Pre-Treated Patient Mesothelioma patients who have received treatment once before, are often called “pre-treated.” Clinicians often have more personalized data available for these patients. This affects the clinician’s treatment strategy. A new study compared the data from nine different mesothelioma clinical trials. These clinical trials spanned standard and experimental treatment options. The results are … Continue reading Treatment Combination for Younger Pre-Treated Mesothelioma Patients »

Comparing 3 Standard Treatments for Mesothelioma

Comparing Three Frontline Treatments for Mesothelioma

There are three standard treatments for malignant pleural mesothelioma. Patients and doctors want to know which is more effective. A new study from the Davidoff Cancer Center in Israel sought to do just that. This study compared three clinical trials of the standard treatments recommended for malignant mesothelioma. All three treatments involved different chemotherapy drugs. Treatment A was cisplatin plus pemetrexed vs cisplatin. Treatment B was cisplatin plus pemetrexed plus bevacizumab vs cisplatin plus pemetrexed. And Treatment C was nivolumab plus ipilimumab vs cisplatin plus pemetrexed. Urgent Need to Identify Effective Treatment Strategies Malignant pleural mesothelioma is the primary cancer of the pleural lining. It is caused by exposure to asbestos. It affected more than 30,000 patients globally in 2020. … Continue reading Comparing 3 Standard Treatments for Mesothelioma »

First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy

Chemotherapy versus Immunotherapy versus Maintenance Therapy

A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only … Continue reading First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy »

Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment

Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment

Immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. Malignant pleural mesothelioma is an aggressive disease. Asbestos exposure has led to globally poor outcomes. While mesothelioma is an uncommon disease, its occurrence is increasing worldwide. Immunotherapy drugs have the potential to make chemotherapy more effective for mesothelioma patients. Researchers theorized immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. The latest results in Molecular and Clinical Oncology suggest that they were right. The findings could have implications for people around the world with mesothelioma. First- and Second-Line Treatment Options for Mesothelioma Patients affected by mesothelioma have a very severe prognosis. Mesothelioma develops after three to four decades after initial exposure to asbestos. For years, the main … Continue reading Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment »

Putting the Newest Mesothelioma “Orphan Drug” Into Perspective

Last week, the FDA announced the approval of a new orphan drug for the treatment of malignant pleural mesothelioma. According to drug manufacturer MTG Biotherapeutics, MTG-201 is an “advanced biologic therapy” that targets a particular gene defect present in cancer cells. This defect prevents cells from producing a protein that is critical in apoptosis or programmed cell death. Without it, mesothelioma cells are free to replicate out of control and migrate to others parts of the body. MTG-201 also appears to trigger the immune system to produce mesothelioma-fighting T-cell lymphocytes that can target and destroy residual cancer cells. The two mechanisms together give it the potential to help combat mesothelioma in a new and potentially more effective way than conventional therapies. … Continue reading Putting the Newest Mesothelioma “Orphan Drug” Into Perspective »

Making Mesothelioma Cells More Susceptible to Chemotherapy

A potential new mesothelioma drug may have moved a step closer to gaining mainstream acceptance for use in sick patients. Doctors studying the drug say they have found a way to make cells more susceptible to its damaging effects. GDC-0980, also known as Apitolisib, is a class I inhibitor of two cell signaling pathways – P13 and mTOR – both of which play critical roles in regulating the life cycle of cells, including mesothelioma cells. Because mesothelioma is so difficult to treat with standard chemotherapy drugs, researchers around the world are exploring ways to improve treatment by manipulating the vital signaling pathways inside mesothelioma cells. Now, doctors at cancer research centers in the US, the UK, and Switzerland say they … Continue reading Making Mesothelioma Cells More Susceptible to Chemotherapy »

Could a Virus-Delivered Gene Slow Mesothelioma Growth?

Researchers in Japan are enrolling mesothelioma patients into a trial to test whether blocking a growth signaling pathway inside mesothelioma cells could slow down this aggressive cancer or even stop its progression. The hepatocyte growth factor (HGF)/c-Met signal pathway is highly active in mesothelioma and many other types of cancer cells, telling them to grow and replicate quickly. In the lab, scientists have shown that the NK4 gene, which shares a molecular structure similar to HGF, can interrupt this signaling pathway and keep cancer cells from growing out of control. In a new study launched this summer by researchers at several Japanese universities, scientists will be testing a method of delivering NK4 to the site of mesothelioma tumors by administering a virus designed … Continue reading Could a Virus-Delivered Gene Slow Mesothelioma Growth? »

Kidney Cancer Drug Slows Mesothelioma Growth in Mice

A drug that has been shown to slow the growth of renal cell carcinoma may have moved a step closer to becoming a viable addition to the arsenal of patients fighting malignant mesothelioma. Temsirolimus is a kinase inhibitor that appears to work against mesothelioma, in part, by blocking the action of a protein that tells cancer cells to replicate. In laboratory tests on isolated tumor cells, temsirolimus effectively blocked the gene pathway known as mammalian target of rapamycin (mTOR) that is responsible for signaling the growth and division of all types of mesothelioma. Now, a new study conducted by scientists in Greece and the UK suggests that the compound may do the same thing in living patients. The doctors induced … Continue reading Kidney Cancer Drug Slows Mesothelioma Growth in Mice »

European Group Issues Updated Treatment Guidelines for Mesothelioma

physician and colleagues

A group of medical researchers has just released an updated set of clinical practice guidelines for treating patients with malignant pleural mesothelioma, one of the rarest and most treatment-resistant forms of cancer. The guidelines, released by the European Society for Medical Oncology and published in the newest issue of the Annals of Oncology, contain six sets of recommendations designed to support clinicians in the management of mesothelioma from diagnosis to treatment and follow-up. Recommendation for Mesothelioma Diagnosis The updated ESMO mesothelioma guidelines recommend that all patients undergo a thorough occupational history with emphasis on asbestos exposure and a CT scan of their chest. They also recommend that all patients with pleural thickening have a biopsy but do not recommend routine … Continue reading European Group Issues Updated Treatment Guidelines for Mesothelioma »

Extended Survival of Peritoneal Mesothelioma with Repeat Treatment

There is some good news on the research front for patients with recurrent peritoneal mesothelioma. Doctors at the University of New South Wales in Australia say that treating these patients again with surgery and heated chemotherapy is extending lives, sometimes for several years. Peritoneal mesothelioma, which accounts for about 20 percent of mesothelioma cases, occurs on the peritoneal membrane that surrounds abdominal organs. Cytoreductive surgery (CRS) aims to remove as much of that diseased tissue as possible. It is often followed by heated intraperitoneal chemotherapy (HIPEC) to kill any remaining mesothelioma cells and to keep new tumors from starting. The CRS/HIPEC combination has become the gold standard first line treatment for peritoneal mesothelioma. But the authors of a new study … Continue reading Extended Survival of Peritoneal Mesothelioma with Repeat Treatment »